Follistim Purple Book BLA 020582

BLA number
020582
Proprietary names
Follistim
Proper names
follitropin beta
Applicant
Organon USA Inc., a subsidiary of Merck & Co., Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Follistimfollitropin beta351(a)75IUFor InjectionSubcutaneous, IntramuscularSingle-Dose VialDiscVoluntarily Revoked1997-09-29
002Follistimfollitropin beta351(a)150IUFor InjectionSubcutaneous, IntramuscularSingle-Dose VialDiscVoluntarily Revoked1997-09-29

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-03-01U001Follistim351(a)DiscOrganon USA Inc., a subsidiary of Merck & Co., Inc.
2023-03-01U002Follistim351(a)DiscOrganon USA Inc., a subsidiary of Merck & Co., Inc.
2020-05-01R001Follistim351(a)DiscOrganon USA Inc., a subsidiary of Merck & Co., Inc.
2020-05-01R002Follistim351(a)DiscOrganon USA Inc., a subsidiary of Merck & Co., Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-03-01001Follistim351(a)DiscVoluntarily Revoked1997-09-29
2023-03-01002Follistim351(a)DiscVoluntarily Revoked1997-09-29
2020-05-01001Follistim351(a)DiscLicensed1997-09-29
2020-05-01002Follistim351(a)DiscLicensed1997-09-29